# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps

> **NCT02170337** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 41 (actual)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps

## Interventions

- **DRUG:** AMG 282
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02170337
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2016-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02170337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02170337, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02170337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*